Starpharma (ASX:SPL) Announces Q3 FY25 Activities Report
Starpharma (ASX:SPL) announces Q3 FY25 report with advancements in partnerships, product launches, and financial performance.
Category: Healthcare
MedAdvisor Limited (ASX:MDR) Releases 3Q FY25 Financial Update
MedAdvisor Limited (ASX:MDR) reports a significant decrease in 3Q FY25 revenue, announces cost-cutting measures and strategic initiatives.
Paradigm Biopharmaceuticals Ltd (ASX:PAR) Announces Phase 3 Trial Launch and Financial Update
Paradigm Biopharmaceuticals (ASX:PAR) announces the launch of its Phase 3 trial for knee osteoarthritis and the receipt of a $6.3 million R&D tax refund.
InteliCare Holdings Ltd (ASX:ICR) Partners with mecwacare for AI Platform Trial at Trescowthick Centre
InteliCare Holdings Ltd (ASX:ICR) partners with mecwacare to trial its AI-driven platform at Trescowthick Centre, enhancing aged care services in Victoria.
4DMedical Limited (ASX:4DX) Reports 103% Revenue Growth and Strategic Milestones
4DMedical Limited (ASX:4DX) achieves 103% YTD revenue growth and secures key strategic partnerships in Q3 FY2025.
Zelira Therapeutics Ltd (ASX:ZLD) Boosts Financial Flexibility with R&D Refund and ATM Facility
Zelira Therapeutics (ASX:ZLD) enhances financial flexibility with a $1.15M R&D refund and a $1M ATM facility to support ongoing developments.
Radiopharm Theranostics (ASX:RAD) Begins Phase 2b U.S. Trial for 18F-RAD101
Radiopharm Theranostics (ASX:RAD) initiates Phase 2b U.S. trial of 18F-RAD101, advancing diagnostic capabilities for brain metastasis.
Orthocell Limited (ASX:OCC) Gains Thai FDA Approval for Remplir™
Orthocell (ASX:OCC) receives Thai FDA approval to launch Remplir™, expanding into the US$84 million nerve repair market.
ResMed Inc. (ASX:RMD) Reports Q1 2025 Financial Results
ResMed Inc. (ASX:RMD) reports Q1 2025 revenues up 8% and diluted EPS of $2.48, declaring a $0.53 dividend per share.
PYC Therapeutics (ASX:PYC) Announces Q1 2025 Shareholder Update
PYC Therapeutics (ASX:PYC) extends cash runway to over $200m and advances polycystic kidney disease program in Q1 2025.